Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1d7e470e09803bd6bf24b2fd176109dd http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_938aeb28275a6960545835cfa8454a44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5073a0063d6be9e25c14d2af0a1ee89 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0014 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-585 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-585 |
filingDate |
2014-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da790361d4e50f99468ef4e6d94bb900 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b85df26feea0316e2045043ff47f6aa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbc2e7f05d6b761d3684e82296ffb372 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_192543aba78086b88ccb0225509d2221 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9eed160aaaa25c7a56d4ed0d29efeab5 |
publicationDate |
2016-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2016136183-A1 |
titleOfInvention |
Pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning |
abstract |
The present invention relates to method and pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning. In particular, the present invention relates to a mineralocorticoid receptor antagonist for topical use in a method for preventing or reducing glucocorticoid-induced corneal or skin thinning in a subject in need thereof. The invention also relates to a topical pharmaceutical composition comprising an amount of at least one glucocorticoid and an amount of at least one mineralocorticoid receptor antagonist or inhibitor of MR expression for use in a method for treating an inflammatory skin disease or an inflammatory disease of the cornea or of the anterior segment of the eye in a subject in need thereof. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10350223-B2 |
priorityDate |
2013-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |